<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476047</url>
  </required_header>
  <id_info>
    <org_study_id>PSOC 2301</org_study_id>
    <secondary_id>NCI-2011-01311</secondary_id>
    <secondary_id>PSOC 2301</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00476047</nct_id>
  </id_info>
  <brief_title>Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission</brief_title>
  <official_title>A Study of 131I-Tositumomab (BexxarÂ®) Consolidation in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well tositumomab and iodine I 131 tositumomab works in
      treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
      that have had their first decrease in or disappearance of signs and symptoms of cancer (first
      remission). Monoclonal antibodies, such as tositumomab and iodine I 131 tositumomab, may
      block cancer growth in different ways by targeting certain cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the progression-free survival at 2 years following administration of
      131I-tositumomab (tositumomab and iodine I 131 tositumomab) in patients with CLL/SLL who
      achieve a complete remission (CR) or partial remission (PR) with prior therapy.

      II. To improve the response rate by administering 131I-tositumomab to patients who have
      achieved a PR not a CR after any prior therapy.

      III. To eliminate residual disease (documented by flow cytometry or polymerase chain reaction
      [PCR]) using 131I-tositumomab in patients who have achieved a CR after any prior therapy.

      SECONDARY OBJECTIVES:

      I. To evaluate the toxicities of 131I-tositumomab in 1st remission patients with previously
      treated CLL/SLL.

      OUTLINE:

      Patients receive tositumomab and iodine I 131 tositumomab intravenously (IV) over 90 minutes
      on day 0 and then again 7-14 days later over 30-60 minutes.

      After completion of study treatment, patients are followed up weekly for 3 months, every 3
      months for 2 years, every 6 months for 3 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of Progression-free Survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>Progression free survival (PFS) is defined as the interval between the first treatment day to the first sign of disease progression. This outcome measures the percentage of participants with PFS at 36 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improved Response Rate After Treatment With 131I-tositumomab for Patients Who Had Evidence of CLL at the End of Initial Chemotherapy</measure>
    <time_frame>3 months after 131I-tositumomab consolidation</time_frame>
    <description>Response rates determined using National Cancer Institute (NCI) working group guidelines plus computed tomography (CT) scan criteria. Participants were assessed for response after initial chemotherapy and again 3 months after 131I-tositumomab treatment.Only patients who had less than a complete response (CR) after initial chemotherapy were assessed for improved response after 131I-tositumomab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Residual Disease (MRD) by Flow Cytometry or Polymerase Chain Reaction (PCR) in Patients Who Had a Complete Remission (CR) After Any Prior Therapy</measure>
    <time_frame>3 months after 131I-tositumomab consolidation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Toxicities of 131I-tositumomab</measure>
    <time_frame>48 months (median)</time_frame>
    <description>Adverse events following treatment of 131I-tositumomab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Lymphoid Leukemia in Remission</condition>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <condition>Stage II Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Small Lymphocytic Lymphoma</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (monoclonal antibody therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Tositumomab and Iodine I 131 Tositumomab</intervention_name>
    <description>Give IV</description>
    <arm_group_label>Treatment (monoclonal antibody therapy)</arm_group_label>
    <other_name>Bexxar</other_name>
    <other_name>Bexxar Therapeutic Regimen</other_name>
    <other_name>Bexxar Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of cluster of differentiation (CD)20+ CLL/SLL; prior to the
             first treatment patients with CLL must have been either Rai stage III/IV disease or
             Rai stage I/II with evidence of disease activity as defined by the National Cancer
             Institute (NCI) 1996 guidelines, and patients with SLL must have been Stage III or IV
             per Ann Arbor staging system

          -  Patient has received prior therapy and is in 1st remission with a partial or complete
             response to treatment

          -  Patients must have no more than 25% of the intratrabecular marrow space involved by
             leukemia in bone marrow biopsy specimens as assessed microscopically after completion
             of treatment; bilateral posterior iliac crest core biopsies are required if the
             percentage of intratrabecular space involved exceeds 10% on a unilateral biopsy; the
             mean of bilateral biopsies must be no more than 25%

          -  Patient must have consented to participate in the study and signed and dated an
             appropriate institutional review board (IRB)-approved consent form that conforms to
             federal and institutional guidelines

          -  Patient must have a Eastern Cooperative Oncology Group (ECOG) performance status of 0,
             1 or 2 (0 = fully active, able to carry on all pre-disease performance without
             restriction; 1 = restricted in physically strenuous activity but ambulatory and
             ambulatory and able to carry out work of a light or sedentary nature, e.g., light
             house work, office work; 2 = ambulatory and capable of all self-care but unable to
             carry out any work activities and is up and about more than 50% of waking hours)

          -  Patient must have an anticipated survival of at least 3 months

          -  Granulocytes &gt;= 1,500/uL within 14 days of planned dosimetric infusion

          -  Platelets &gt;= 100,000/uL within 14 days of planned dosimetric infusion

          -  White blood count =&lt; 20,000/mm^3

          -  Serum creatinine &lt; 2 times upper limit of normal

          -  Total bilirubin &lt; 2 times upper limit of normal

          -  Aspartate aminotransferase (AST) &lt; 5 times upper limit of normal

          -  Males and females must agree to use a contraceptive method from enrollment to 6 months
             after receiving I-131 labeled tositumomab

        Exclusion Criteria:

          -  Patients who have received prior radiolabeled antibody

          -  Patients with active hemolysis

          -  Patients must not require sustained transfusion support of blood products

          -  Patients in 2nd remission or beyond

          -  Patients who have undergone treatment with either stem cell or bone marrow transplant

          -  Patients with active obstructive hydronephrosis

          -  Patients with evidence of any significant systemic illness, active hepatitis B
             infection or other active infection at the time of study entry

          -  Patients with New York Heart Association class III or IV heart disease or other
             serious illness that would preclude evaluation

          -  Patients with known human immunodeficiency virus (HIV) infection

          -  Patients who are pregnant or nursing

          -  Patients with prior malignancy other than CLL/SLL, except for adequately treated skin
             cancer (basal cell or squamous cell carcinoma), in situ cervical cancer, or other
             cancer for which the patient has been disease-free for 5 years unless approved by the
             principal investigator (PI)

          -  Patients with active brain or leptomeningeal involvement by malignancy

          -  Patients who have, in the opinion of the investigator, other medical, social, or
             psychosocial factors that may negatively impact compliance or their safety by
             participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mazyar Shadman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <results_first_submitted>April 14, 2017</results_first_submitted>
  <results_first_submitted_qc>October 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2017</results_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Mazyar Shadman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Monoclonal Antibody Therapy)</title>
          <description>Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
Tositumomab and Iodine I 131 Tositumomab: Give IV
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Monoclonal Antibody Therapy)</title>
          <description>Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
Tositumomab and Iodine I 131 Tositumomab: Give IV
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="38" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CLL or SLL</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CLL (Chronic lymphocytic leukemia)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>SLL (Small lymphocytic leukemia)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>FR (fludaribine and rituximab)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FCR(fludaribine, cyclophosphamide and rituximab)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>BR (bendamustine and rituximab)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>R-CHOP</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease status before 131 I-tositumomab</title>
          <description>CRITERIA FOR RESPONSE Criteria for response are specified by the NCI working group guidelines; in addition, patients will be required to meet computed tomography (CT) scan criteria as defined in the protocol.
Complete response (CR) Partial response (PR) Progressive Disease (PD) Stable Disease (SD)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CR (complete response)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PR (partial response)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minimal Residual Disease (MRD) status before 131 I-tositumomab</title>
          <description>MRD was assessed on bone marrow samples using 8 color flow cytometry to detect CLL/SLL cells. Any level of residual disease by flow cytometry or cytogenetics was considered MRD positive. Negativity of both tests was required to classify a patient as MRD negative.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Probability of Progression-free Survival (PFS)</title>
        <description>Progression free survival (PFS) is defined as the interval between the first treatment day to the first sign of disease progression. This outcome measures the percentage of participants with PFS at 36 months.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Monoclonal Antibody Therapy)</title>
            <description>Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
Tositumomab and Iodine I 131 Tositumomab: Give IV
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of Progression-free Survival (PFS)</title>
          <description>Progression free survival (PFS) is defined as the interval between the first treatment day to the first sign of disease progression. This outcome measures the percentage of participants with PFS at 36 months.</description>
          <units>percentage probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="25" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improved Response Rate After Treatment With 131I-tositumomab for Patients Who Had Evidence of CLL at the End of Initial Chemotherapy</title>
        <description>Response rates determined using National Cancer Institute (NCI) working group guidelines plus computed tomography (CT) scan criteria. Participants were assessed for response after initial chemotherapy and again 3 months after 131I-tositumomab treatment.Only patients who had less than a complete response (CR) after initial chemotherapy were assessed for improved response after 131I-tositumomab.</description>
        <time_frame>3 months after 131I-tositumomab consolidation</time_frame>
        <population>Participants who had a partial response (PR) after initial chemotherapy. Response assessed using NCI working group guidelines + CT criteria as described in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Monoclonal Antibody Therapy)</title>
            <description>Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
Tositumomab and Iodine I 131 Tositumomab: Give IV</description>
          </group>
        </group_list>
        <measure>
          <title>Improved Response Rate After Treatment With 131I-tositumomab for Patients Who Had Evidence of CLL at the End of Initial Chemotherapy</title>
          <description>Response rates determined using National Cancer Institute (NCI) working group guidelines plus computed tomography (CT) scan criteria. Participants were assessed for response after initial chemotherapy and again 3 months after 131I-tositumomab treatment.Only patients who had less than a complete response (CR) after initial chemotherapy were assessed for improved response after 131I-tositumomab.</description>
          <population>Participants who had a partial response (PR) after initial chemotherapy. Response assessed using NCI working group guidelines + CT criteria as described in the protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Participants who achieved a CR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants who did not achieve a CR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimal Residual Disease (MRD) by Flow Cytometry or Polymerase Chain Reaction (PCR) in Patients Who Had a Complete Remission (CR) After Any Prior Therapy</title>
        <time_frame>3 months after 131I-tositumomab consolidation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient Who Achieved CR After Any Prior Therapy</title>
            <description>Patients who received study treatment and who had achieved a complete remission (CR) after any prior therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Residual Disease (MRD) by Flow Cytometry or Polymerase Chain Reaction (PCR) in Patients Who Had a Complete Remission (CR) After Any Prior Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative MRD status</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive MRD status</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Toxicities of 131I-tositumomab</title>
        <description>Adverse events following treatment of 131I-tositumomab</description>
        <time_frame>48 months (median)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Monoclonal Antibody Therapy)</title>
            <description>Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
Tositumomab and Iodine I 131 Tositumomab: Give IV
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Toxicities of 131I-tositumomab</title>
          <description>Adverse events following treatment of 131I-tositumomab</description>
          <units>participants with this toxicity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypogammaglobulinemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia related sepsis/typhlitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basal cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Monoclonal Antibody Therapy)</title>
          <description>Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
Tositumomab and Iodine I 131 Tositumomab: Give IV
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia Grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neutropenia Grade 3 or 4</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia Grade 3 or 4</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mazyar Shadman, MD</name_or_title>
      <organization>Fred Hutchinson Cancer Research Ctr</organization>
      <phone>2066675467</phone>
      <email>mshadman@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

